Prescribing contraceptives for women with schizophrenia

Journal of Psychiatric Practice

Volumn 17, Issue 4, 2011, Pages 258-269

  Seeman, Mary V ^a   Ross, Ruth ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

contraceptives; counseling; hormones; schizophrenia; sex; women

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; COPPER INTRAUTERINE DEVICE; CYTOCHROME P450 3A4; ESTROGEN; FELBAMATE; LAMOTRIGINE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; MISOPROSTOL; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROGESTERONE; PROSTAGLANDIN; SPERMICIDAL AGENT; TOPIRAMATE; ULIPRISTAL; VALPROIC ACID;

ABDOMINAL CRAMP; ACNE; AMENORRHEA; BARRIER CONTRACEPTION; BIPOLAR DISORDER; BODY MASS; BONE DENSITY; BREAST CANCER; BREAST TENDERNESS; CALCIUM INTAKE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; COITUS; CONDOM; CONTRACEPTION; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG INDUCED HEADACHE; DYSPAREUNIA; EMERGENCY CONTRACEPTION; FAMILY PLANNING; FEMALE STERILIZATION; FLUID RETENTION; FRACTURE; GYNECOLOGICAL EXAMINATION; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INFECTION RISK; INTERMETHOD COMPARISON; INTRAUTERINE CONTRACEPTIVE DEVICE; LIBIDO; LIPID STORAGE; LOW DRUG DOSE; MENSTRUATION; MENSTRUATION DISORDER; MENTAL HEALTH; MIGRAINE; MOOD CHANGE; NAUSEA; OBESITY; OVARY CYST; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT SAFETY; PELVIC INFLAMMATORY DISEASE; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRESCRIPTION; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; SYSTEMATIC REVIEW (TOPIC); TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREMOR; UNSAFE SEX; UNWANTED PREGNANCY; UTERINE TUBE LIGATION; UTERUS PERFORATION; VAGINA RING; VAGINAL LAVAGE; VAGINITIS; VEIN THROMBOSIS; VOMITING; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CONTRACEPTION; CONTRACEPTIVE AGENTS; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; SCHIZOPHRENIA; WOMEN;

EID: 80051719264     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000400263.52913.dc     Document Type: Review

References (83)

1. Akers AY, Gold MA, Borrero S, et al. Structured contraceptive counseling-A randomized controlled trial. J Womens Health 2010;19:1163-70.
2. Haboubi NH, Lincoln N. Views of health professionals on discussing sexual issues with patients. Disabil Rehabil 2003;25:291-6. (Pubitemid 36285054)
3. Wright ER, Wright DE, Perry BL, et al. Stigma and the sexual isolation of people with serious mental illness. Social Problems 2007;54:78-98.
4. Currier GW, Simpson GM. Psychopharmacology: Antipsy - chotic medications and fertility. Psychiatr Serv 1998;49: 175-6. (Pubitemid 28071423)
5. Torrey EF, Yolken RH. Psychiatric genocide: Nazi attempts to eradicate schizophrenia. Schizophr Bull 2010;36:26-32.
6. Abel K, Rees S. Reproductive and sexual health of women service users: Whats the fuss? Adv Psychiatr Treat 2010;16:279-80.
7. Matevosyan NR. Reproductive health in women with serious mental illnesses: A review. Sexuality Disab 2009;27: 109-18.
8. Burt VK, Hendrick VC. Gender issues in the treatment of mental illness. Focus 2006;4:66-80.
9. Pehlivanoglu K, Tanriover O, Tomruk N, et al. Family planning needs and contraceptive use in female psychiatric outpatients. Turkish J Fam Med Primary Care 2007; 1:32-5.
10. Gomes Guedes T, Ferreira Moura ER, De Almeida PC. Particularities of family planning in women with mental disorders. Revista Latino-Americana de Enfermagem 2009;17:639-44.
11. Nogueira Campos L, Guimarães MDC, Andrade Carmo R, et al. HIV, syphilis, and hepatitis B and C prevalence among patients with mental illness: A review of the literature. Cad. Saúde Pública 2008;24:S07-20.
12. Raja M, Azzoni A. Sexual behavior and sexual problems among patients with severe chronic psychoses. Eur Psychiatry 2003;18:70-6. (Pubitemid 36528526)
13. McNeil TF, Schubert EW, Cantor-Graae E, et al. Unwanted pregnancy as a risk factor for offspring schizophreniaspectrum and affective disorders in adulthood: A prospective high-risk study. Psychol Med 2009;39:957-65.
14. Ellman LM, Deicken RF, Vinogradov S, et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res 2010;121:46-54.
15. Bukaab SL, Cannon TD, Torrey EF, et al. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry 2008;63:809-15. (Pubitemid 351400765)
16. Bulik CM, Hoffman ER, Von Holle A, et al. Unplanned pregnancy in women with anorexia nervosa. Obstet Gynecol 2010;116:1136-40.
17. Choe JY, Teplin LA, Abram KM. Perpetration of violence, violent victimization, and severe mental illness: Balancing public health concerns. Psychiatr Serv 2008;59:153-64.
18. Dehlendorf C, Levy K, Ruskin R, et al. Health care providers knowledge about contraceptive evidence: A barrier to quality family planning care? Contraception 2010; 81:292-8.
19. The European Natural Family Planning Study Groups. European multicenter study of natural family planning (1989-1995): Efficacy and drop-out. Adv Contracept 1999;15:69-83.
20. Tommaselli GA, Guida M, Palomba S, et al. The importance of user compliance on the effectiveness of natural family planning programs. Gynecol Endocrinol 2000;14: 81-9. (Pubitemid 30307215)
21. Choi J, Chan S, Wiebe E. Natural family planning: Physicians knowledge, attitudes, and practice. J Obstet Gynaecol Can 2010;32:673-8.
22. Witte SS, Stefano K, Hawkins C. Can Medicaid reimbursement help give female condoms a second chance in the United States? Am J Public Health 2010;100:1835-40.
23. Batár I. State-of-the-art of non-hormonal methods of contraception: II. Chemical barrier contraceptives. Eur J Contracept Reprod Health Care 2010;15:89-95.
24. Cagnacci A, Ferrari S. Evolution and future of contraception. Minerva Ginecol 2010;62:303-17.
25. Martino JL, Vermund SH. Vaginal douching: Evidence for risks or benefits to womens health. Epidemiol Rev 2002;24:109-24. (Pubitemid 36553834)
26. Batár I, Sivin I. State-of-the-art of non-hormonal methods of contraception: I. Mechanical barrier contraception. Eur J Contracept Reprod Health Care 2010;15:67-88.
27. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010;29:1-44.
28. Anonymous. What role for Qlaira in contraception? Drug Ther Bull 2010;48:102-5.
29. Lee M, Morgan M, Rapkin A. Clitoral and vulvar vestibular sensation in women taking 20 mcg ethinyl estradiol combined oral contraceptives: A preliminary study. J Sex Med 2011;8:213-8.
30. Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: Cohort evidence from Royal College of General Practitioners Oral Contra - ception Study. BMJ 2010;11;340:c927.
31. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010;82:22-9.
32. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009;53: 22-31.
33. Shah MB, Hoffstetter S. Contraception and sexuality. Minerva Ginecol 2010;62:33-47.
34. Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: A potential new treatment approach. Arch Gen Psychiatry 2008;65:955-60.
35. Riecher-Rössler A. Oestrogen effects in schizophrenia and their potential therapeutic implications-review. Arch Womens Ment Health 2002;5:111-8. (Pubitemid 35387789)
36. Riecher-Rössler A, de Geyter C. The forthcoming role of treatment with oestrogens in mental health. Swiss Med Wkly 2007;137: 565-72. (Pubitemid 350004694)
37. Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors: Basic pathophysiology. Crit Care Med 2010;38: S3-9.
38. Jönsson AK, Horváth-Puhó E, Hägg S, et al. Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clin Epidemiol 2009;1:19-26.
39. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: Nested casecontrol study. BMJ 2010;341:c4245
40. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: A review. Contraception 2010;82:314-23.
41. Skouby SO. Hormonal contraception in obesity, the metabolic syndrome, and diabetes. Ann N Y Acad Sci 2010; 1205:240-4.
42. Anonymous. Hormonal contraceptives for contraception in overweight or obese women. Obstet Gynecol 2010;116: 1206-7.
43. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410-7.
44. Verhaeghe J. Hormonal contraception in women with the metabolic syndrome: A narrative review. Eur J Contracept Reprod Health Care 2010;15:305-13.
45. Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 2010;95:4909-16.
46. Rahman M, Berenson AB. Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate. Obstet Gynecol 2010;115:35-40.
47. Civic D, Scholes D, Ichikawa L, et al. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception 2000;61:385-90. (Pubitemid 30665814)
48. French R, Van Vliet H, Cowan F, et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2004;3: CD001776
49. Rubin SE, Winrob I. Urban female family medicine patients perceptions about intrauterine contraception. J Womens Health (Larchmt) 2010;19:735-40.
50. Anonymous. Intrauterine devices: An effective alternative to oral hormonal contraception. Prescrire Int 2009;18: 125-30.
51. Saarikoski S. Chronic illness and contraception. Duodecim 1987;103:593-7.
52. Cropsey KL, Matthews C, Campbel S, et al. Long-term, reversible contraception use among high-risk women treated in a university-based gynecology clinic: Comparison between IUD and Depo-Provera. J Womens Health (Larchmt) 2010;19:349-53.
53. Cremer M, Masch R. Emergency contraception: Past, present and future. Minerva Ginecol 2010;62:361-71.
54. Gemzell-Danielsson K. Mechanism of action of emergency contraception. Contraception 2010;82:404-9.
55. Russo JA, Creinin MD. Ulipristal acetate for emergency contraception. Drugs Today (Barc) 2010;46:655-60.
56. Spitz IM. Mifepristone: Where do we come from and where are we going? Clinical development over a quarter of a century. Contraception 2010;82:442-52.
57. Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010;15:4-16.
58. Banck DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokin 1990;18: 472-84.
59. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996;31:198-214. (Pubitemid 26335906)
60. Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009;72:911-4.
61. Wegner I, Edelbroek PM, Bulk S, et al. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009;73:1388-93.
62. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;43: 763-80. (Pubitemid 39382219)
63. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010;10: 119-40.
64. Reddy DS. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol 2010;3:183-92.
65. Gabbay V, ODowd MA, Mamamtavrishvili M, et al. Clozapine and oral contraceptives: A possible drug interaction. J Clin Psychopharmacol 2002;22:621-2. (Pubitemid 35416789)
66. Brown D, Goosen TC, Chetty M, et al. Effect of oral contraceptives on the transport of chlorpromazine across the CACO-2 intestinal epithelial cell line. Eur J Pharm Biopharm 2003;56:159-65. (Pubitemid 37072098)
67. Chetty M, Miller R. Oral contraceptives increase the plasma concentrations of chlorpromazine. Ther Drug Monit 2001;23:556-8. (Pubitemid 32912280)
68. Muirhead GJ, Harness J, Holt PR, et al. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol 2000;49: 49S-56S. (Pubitemid 30151053)
69. Kroop LA. Drug interactions with smoking. Am J Health- Syst Pharm 2007; 64:1917-21.
70. Pretorius E, Oberholzer HM, van der Spuy WJ, et al. Smoking and coagulation: The sticky fibrin phenomenon. Ultrastruct Pathol 2010;34:236-9.
71. Harper CC, Brown BA, Foster-Rosales A, et al. Hormonal contraceptive method choice among young, low-income women: How important is the provider? Patient Educ Couns 2010;81:349-54.
72. Sawhill I, Thomas A, Monea E. An ounce of prevention: Policy prescriptions to reduce the prevalence of fragile families. Future Child 2010;20:133-55.
73. Moos MK, Bartholomew NE, Lohr KN. Counseling in the clinical setting to prevent unintended pregnancy: An evidence- based research agenda. Contraception 2003;67: 115-32. (Pubitemid 36174011)
74. Weisman CS, Maccannon DS, Henderson JT, et al. Contraceptive counseling in managed care: Preventing unintended pregnancy in adults. Womens Health Issues 2002;12:79-95. (Pubitemid 34168526)
75. Hock-Long L, Whittaker P.G, Herceg-Baron R. Family planning service delivery research: A call to focus on the dynamics of contraceptive use. Perspect Sex Reprod Health 2010;42:10-11.
76. Henderson JT, Raine T, Schalet A, et al. "I wouldnt be this firm if I didnt care": Preventive clinical counseling for reproductive health. Patient Educ Couns 2011;82:254-9.
77. Lopez LM, Tolley EE, Grimes DA, et al. Theory-based strategies for improving contraceptive use: A systematic review. Contraception 2009;79:411-7.
78. Petersen R, Payne P, Albright J, et al. Applying motivational interviewing to contraceptive counseling: ESP for clinicians. Contraception 2004;69:213-7. (Pubitemid 38224220)
79. Kulkarni J. Special issues in managing long-term mental illness in women. Int Rev Psychiatry 2010;22:183-90.
80. Coverdale JH, Bayer TL, McCullough LB, et al. Respecting the autonomy of chronic mentally ill women in decisions about contraception. Hosp Community Psychiatry 1993; 44:671-4. (Pubitemid 23193655)
81. Coverdale JH, Turbott S, Roberts H. Family planning needs and STD risk behaviours of female psychiatric outpatients. Br J Psychiatry 1997;171:69-72.
82. Miller LJ. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull 1997;23: 623-35. (Pubitemid 27485971)
83. Lloyd C, Williams PL, King R. A sexual health programme implemented in a psychiatric inpatient unit. NZ J Occupational Therapy 2005;52:26-32.